{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T07:15:48Z","timestamp":1761808548581},"reference-count":13,"publisher":"Georg Thieme Verlag KG","issue":"08","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Laryngorhinootologie"],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:p>\n            Hintergrund Neuroendokrine Tumoren (NET) sind benigne oder maligne Neoplasien, die entwicklungsgeschichtlich der Neuralleiste oder paraganglion\u00e4ren Zellen des vegetativen Nervensystems entstammen. Die alte Bezeichnung Karzinoid (karzinom\u00e4hnlicher Tumor) ist noch sehr verbreitet, jedoch inzwischen obsolet. Lediglich 0,5\u20132 % aller Neoplasien des Menschen sind neuroendokrine Tumoren, welche \u00fcberwiegend gastrointestinal oder bronchopulmonal lokalisiert sind. Die Inzidenz betr\u00e4gt 9.263\/100.000. Jedoch ist nur 1 % der Kopf-Hals-Tumore neuroendokriner Genese. Fallzahlstarke Langzeitstudien und Leitlinien zur Diagnose und Therapie im Kopf-Hals-Bereich fehlen. Ziel dieser Arbeit ist der wertende Vergleich bekannter Therapiestrategien und daraus folgender Krankheitsverl\u00e4ufe sowie deren Vergleich mit dem Schrifttum anhand eigener F\u00e4lle unterschiedlicher Lokalisation und Ausdehnung.<\/jats:p><jats:p>\n            Patienten und Methoden In unserer Klinik wurden zwischen 2010 und 2017 14 Patienten  mit neuroendokrinen Tumoren im Kopf-Hals-Bereich behandelt. Acht Patienten davon wurden prim\u00e4r operativ mit adjuvanter Radiochemotherapie (RCT) versorgt. Sechs Patienten erhielten eine prim\u00e4re Radiochemotherapie in kurativer Absicht. Ein Patient erhielt aufgrund des Tumorprogresses nach der prim\u00e4ren Radiochemotherapie eine weitere Chemotherapie mit palliativer Indikation.<\/jats:p><jats:p>\n            Ergebnisse Die Tumorlokalisationen verteilen sich auf den Larynx (n = 7), die Glandula parotis (n = 2) und auf die Nasenhaupt- und -nebenh\u00f6hlen (n=5). Von den 8 operierten Patienten konnte in 6 F\u00e4llen eine in-sano-Resektion (R0) erreicht werden. Die im Kollektiv gemessene Gesamt\u00fcberlebensrate betr\u00e4gt im Mittel 19\u00b16 Monate. Von den 14 untersuchten Patienten erlitten 2 Patienten ein Rezidiv, wovon ein Patient nach 7 Monaten verstarb und ein Patient 32 Monate nach der Nachresektion Rezidiv-frei lebt. In zwei F\u00e4llen sprach das NET nicht auf die kombinierte RCT an und die Patienten verstarben jeweils nach 6 und 13 Monaten. Die \u00dcberlebenszeit ist abh\u00e4ngig vom T-Stadium des NET sowie vom Erreichen einer R0-Resektion. Die R0-Resektion bietet eine h\u00f6here \u00dcberlebenswahrscheinlichkeit als die prim\u00e4re RCT.<\/jats:p><jats:p>\n            Schlussfolgerung Patienten mit NET des Kopf-Hals-Bereiches m\u00fcssen in spezialisierten Zentren interdisziplin\u00e4r behandelt werden. Zur Erfassung dieser Daten ist eine Tumordatenbank notwendig. Jedoch sind aufgrund der niedrigen Inzidenz keine Studien auf hohem Evidenzniveau zu erwarten. Nach Diagnosestellung sollte ohne zeitliche Verz\u00f6gerung die im Rahmen einer int. TuKo individuelle auf den Patienten zugeschnittene Therapie erfolgen.<\/jats:p>","DOI":"10.1055\/a-1976-9641","type":"journal-article","created":{"date-parts":[[2022,12,24]],"date-time":"2022-12-24T00:40:15Z","timestamp":1671842415000},"page":"585-590","source":"Crossref","is-referenced-by-count":1,"title":["Neuroendokrine Tumoren im Kopf-, Halsbereich"],"prefix":"10.1055","volume":"102","author":[{"given":"Thien An","family":"Duong Dinh","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology and Head-, Neck Surgery, University Hospital RWTH Aachen, Aachen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Till","family":"Braunschweig","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University Hospital RWTH Aachen, Aachen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justus","family":"Ilgner","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Hals-, Nasen-, Ohrenheilkunde und Plastische Kopf- und Halschirurgie, Universit\u00e4tsklinikum RWTH Aachen, Aachen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Westhofen","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Hals-Nasen-Ohren-Heilkunde, Plastische Kopf- und Hals-Chirurgie, RWTH, Aachen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2022,12,23]]},"reference":[{"issue":"03","key":"ref1","doi-asserted-by":"publisher","first-page":"33","DOI":"10.4251\/wjgo.v3.i3.33","article-title":"Epidemiology of cancer of the small intestine","volume":"3","author":"SY Pan","year":"2011","journal-title":"World J Gastrointest Oncol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"R163","DOI":"10.1530\/ERC-12-0024","article-title":"Neuroendocrine tumor disease: an evolving landscape","volume":"19","author":"A Frilling","year":"2012","journal-title":"Endocr Relat Cancer"},{"issue":"18","key":"ref3","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","article-title":"One hundred years after \u201ccarcinoid\u201d: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States","volume":"26","author":"JC Yao","year":"2008","journal-title":"J Clin Oncol"},{"issue":"02","key":"ref4","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/PAS.0b013e318236d822","article-title":"Head and neck large cell neuroendocrine carcinoma should be separated from atypical carcinoid on the basis of different clinical features, overall survival, and pathogenesis","volume":"36","author":"HL Kao","year":"2012","journal-title":"Am J Surg Pathol"},{"key":"ref5","volume-title":"WHO classification of head and neck tumours","author":"AK El-Naggar","year":"2017"},{"issue":"08","key":"ref7","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.oraloncology.2006.01.002","article-title":"Neuroendocrine neoplasms of the larynx:advances in identification, understanding, and management","volume":"42","author":"A Ferlito","year":"2006","journal-title":"Oral Oncol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1002\/hed.23666","article-title":"Clinical recommendations on the treatment of neuroendocrine carcinoma of the larynx: A meta-analysis of 436 reported cases","volume":"37","author":"TP Van der Laan","year":"2015","journal-title":"Head Neck"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1159\/000276220","article-title":"Small cell neuroendocrine carcinoma of the larynx. A critical review of the literature","volume":"53","author":"DR Gnepp","year":"1991","journal-title":"ORL J Otorhinolaryngol Relat Spec"},{"issue":"03","key":"ref10","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s12105-013-0431-6","article-title":"Moderately differentiated neuroendocrine carcinoma (atypical carcinoid) of the parotid gland: report of three cases with contemporary review of salivary neuroendocrine carcinomas","volume":"7","author":"N Said-Al-Naief","year":"2013","journal-title":"Head and Neck Pathology"},{"issue":"03","key":"ref11","doi-asserted-by":"publisher","DOI":"10.1177\/014556131209100317","article-title":"Neuroendocrine carcinoma of the head and neck: a 20-year case series","volume":"91","author":"R Meacham","year":"2012","journal-title":"Ear, Nose and Throat Journal"},{"issue":"10","key":"ref12","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1007\/s11864-019-0678-6.","article-title":"Molecular Imaging and Therapy for Neuroendocrine Tumors","volume":"20","author":"H Desai","year":"2019","journal-title":"Curr Treat Options Oncol"},{"issue":"01","key":"ref13","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1177\/030089160609200112","article-title":"Neuroendocrine tumors of the larynx: a clinical report and literature review","volume":"92","author":"G Procopio","year":"2006","journal-title":"Tumori"},{"issue":"S 02","key":"ref14","doi-asserted-by":"publisher","first-page":"S149","DOI":"10.1055\/s-0034-1390014","article-title":"Esthesioneuroblastoma, neuroendocrine carcinoma, and sinonasal undifferentiated carcinoma: differentiation in diagnosis and treatment","volume":"18","author":"SY Su","year":"2014","journal-title":"Int Arch Otorhinolaryngol"}],"container-title":["Laryngo-Rhino-Otologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1976-9641.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,3]],"date-time":"2023-08-03T23:43:04Z","timestamp":1691106184000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1976-9641"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,23]]},"references-count":13,"journal-issue":{"issue":"08","published-online":{"date-parts":[[2023,8,3]]},"published-print":{"date-parts":[[2023,8]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1976-9641","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0935-8943","1438-8685"],"issn-type":[{"value":"0935-8943","type":"print"},{"value":"1438-8685","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,23]]}}}